Article Text

Download PDFPDF
EAHP news
EAHP general assembly updates position paper on clinical trials
  1. Stephanie Kohl
  1. Policy & Advocacy, European Association of Hospital Pharmacists, Brussels, Belgium
  1. Correspondence to Stephanie Kohl, Policy & Advocacy, European Association of Hospital Pharmacists, 1200 Brussels, Belgium; Stephanie.Kohl{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Clinical trials are essential for continuously improving patient outcomes and their quality of life. Hospital pharmacists, as members of the multidisciplinary team, are needed to safely manage them. With the entry into application of the Clinical Trial Regulation, EAHP decided to update its Position Paper on Clinical Trials in 2022.

One of the key contributions of the pharmacist is the promotion of patient safety by collaborating in the development of a research protocol, reviewing as a member of an advisory committee, establishing mechanisms that contribute to safety, and assuring compliance with local and national regulations and standards. Hospital pharmacists are at the forefront of patient care and consequently also have a significant impact on patient management and thus should be further integrated into the work of ethics committees.

The position paper of EAHP touches on the role of hospital pharmacists in clinical trials, the involvement of different patient groups, the improvements in Europe’s clinical trial landscape and the role of ethics committees in clinical trials. It contains several calls to action, namely

  • EAHP calls on national governments to recognise the important roles that hospital pharmacists play in clinical trials by requiring their involvement to increase patient safety

  • EAHP encourages regulators to further improve training on clinical trials …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.